Negotiating Dedicated Bioreactor Capacity with Global CDMO Manufacturers
CDMO viral vector capacity is constrained globally. Here is how clinical-stage biotechs secure guaranteed manufacturing slots without punitive take-or-pay penalties.
Vishal VermaCTO & Co-Founder, Dehurdle
March 02, 20234 min read
The CDMO Capacity Reservation Script
Recommended Spoken Script
"We are reserving two 500L viral vector bioreactor suites for Q3 clinical manufacturing. In exchange for a 2-year rolling production commitment with a $2M deposit, we require a flexible 60-day slot deferral window without take-or-pay penalties if clinical trial patient dosing experiences schedule shifts."
The 2-Minute Practice Drill
2-Minute Spoken Drill
The 2-Minute Practice Drill
Practice CDMO contract negotiations in Dehurdle.
Follow Dehurdle on Google
Add Dehurdle to your Google Preferred Sources to see our playbooks in your AI Overviews and Google Search.